The Economic Burden of Elevated Blood Glucose Levels in 2017: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes
- PMID: 30940641
- PMCID: PMC6702607
- DOI: 10.2337/dc18-1226
The Economic Burden of Elevated Blood Glucose Levels in 2017: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes
Abstract
Objective: This study was conducted to update national estimates of the economic burden of undiagnosed diabetes, prediabetes, and gestational diabetes mellitus (GDM) in the United States for year 2017 and provide state-level estimates. Combined with published estimates for diagnosed diabetes, these updated statistics provide a detailed picture of the economic costs associated with elevated blood glucose levels.
Research design and methods: This study estimated medical expenditures exceeding levels occurring in the absence of diabetes or prediabetes and the indirect economic burden associated with reduced labor force participation and productivity. Data sources analyzed included Optum medical claims for ∼5.8 million commercially insured patients continuously enrolled from 2013 to 2015, Medicare Standard Analytical Files containing medical claims for ∼2.8 million Medicare patients in 2014, and the 2014 Nationwide Inpatient Sample containing ∼7.1 million discharge records. Other data sources were the U.S. Census Bureau, Centers for Disease Control and Prevention, and Centers for Medicare & Medicaid Services.
Results: The economic burden associated with diagnosed diabetes (all ages), undiagnosed diabetes and prediabetes (adults), and GDM (mothers and newborns) reached nearly $404 billion in 2017, consisting of $327.2 billion for diagnosed diabetes, $31.7 billion for undiagnosed diabetes, $43.4 billion for prediabetes, and nearly $1.6 billion for GDM. Combined, this amounted to an economic burden of $1,240 for each American in 2017. Annual burden per case averaged $13,240 for diagnosed diabetes, $5,800 for GDM, $4,250 for undiagnosed diabetes, and $500 for prediabetes.
Conclusions: Updated statistics underscore the importance of reducing the burden of prediabetes and diabetes through better detection, prevention, and treatment.
© 2019 by the American Diabetes Association.
Figures
Comment in
-
Understanding the Economic Costs of Diabetes and Prediabetes and What We May Learn About Reducing the Health and Economic Burden of These Conditions.Diabetes Care. 2019 Sep;42(9):1609-1611. doi: 10.2337/dci19-0017. Diabetes Care. 2019. PMID: 31431494 Free PMC article. No abstract available.
Comment on
-
Understanding the Economic Costs of Diabetes and Prediabetes and What We May Learn About Reducing the Health and Economic Burden of These Conditions.Diabetes Care. 2019 Sep;42(9):1609-1611. doi: 10.2337/dci19-0017. Diabetes Care. 2019. PMID: 31431494 Free PMC article. No abstract available.
References
-
- American Diabetes Association 3. Comprehensive medical evaluation and assessment of comorbidities: Standards of Medical Care in Diabetes–2018. Diabetes Care 2018;41(Suppl. 1):S28–S37 - PubMed
-
- Dall TM, Yang W, Halder P, et al. The economic burden of elevated blood glucose levels in 2012: diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes. Diabetes Care 2014;37:3172–3179 - PubMed
-
- Zhang Y, Dall TM, Chen Y, et al. Medical cost associated with prediabetes. Popul Health Manag 2009;12:157–163 - PubMed
-
- Centers for Disease Control and Prevention; National Center for Chronic Disease Prevention and Health Promotion. National Diabetes Statistics Report, 2017 [Internet], 2017. Available from https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-stat.... Accessed 12 November 2018
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
